Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Imdelltra, Balversa, 2 More New Drugs Skip March Listing
Four of the 16 new medicines approved in Japan late last year will be taking a pass on the NHI price listing in March, including Amgen’s Imdelltra (tarlatamab) and Janssen Pharmaceutical’s (J&J) Balversa (erdafitinib), Jiho has learned. Jiho compared the…
To read the full story
Related Article
- Amgen’s Imdelltra, CSL’s Andembry to Join NHI Price List on April 16
April 10, 2025
- Zepbound, Qalsody, and More New Drugs Set for Japan Listing on March 19
March 13, 2025
- Japan Approves Zepbound, Qalsody, and Lots More Drugs
December 27, 2024
REGULATORY
- METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
- Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
- Health Insurance Reform Bill Sails Through Lower House
April 30, 2026
- MOF Pushes for Full-Scale FY2027 Off-Year Drug Price Revision Ahead of “Spring” Proposal
April 28, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…